blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3672953

EP3672953 - BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.06.2022
Database last updated on 28.06.2024
FormerThe patent has been granted
Status updated on  25.06.2021
FormerGrant of patent is intended
Status updated on  25.03.2021
FormerRequest for examination was made
Status updated on  29.05.2020
FormerThe international publication has been made
Status updated on  02.03.2019
Formerunknown
Status updated on  29.08.2018
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Acesion Pharma ApS
Ole Maaløes Vej 3
2200 Copenhagen N / DK
[2020/27]
Inventor(s)01 / SØRENSEN, Ulrik
Ole Maaloes Vej 3
2200 Copenhagen / DK
02 / METE, Antonio
Ole Maaloes Vej 3
2200 Copenhagen / DK
 [2020/27]
Representative(s)Kjerrumgaard, Lars Bo, et al
Nex & Phister Law & IP ApS
Cobis Ole Maaløes Vej 3
2200 København N / DK
[N/P]
Former [2021/30]Kjerrumgaard, Lars Bo, et al
Nex & Phister ApS
Cobis Ole Maaløes Vej 3
2200 København N / DK
Former [2020/27]Kjerrumgaard, Lars Bo
LBKPATENT APS
Cobis Ole Maaløes Vej 3
2200 Copenhagen / DK
Application number, filing date18755828.322.08.2018
[2020/27]
WO2018EP72621
Priority number, dateEP2017002037823.08.2017         Original published format: EP 17020378
[2020/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019038315
Date:28.02.2019
Language:EN
[2019/09]
Type: A1 Application with search report 
No.:EP3672953
Date:01.07.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 28.02.2019 takes the place of the publication of the European patent application.
[2020/27]
Type: B1 Patent specification 
No.:EP3672953
Date:28.07.2021
Language:EN
[2021/30]
Search report(s)International search report - published on:EP28.02.2019
ClassificationIPC:C07D403/12, C07D401/12, C07D235/30, C07D405/12, C07D413/12, A61P9/06, A61K31/4184
[2020/27]
CPC:
C07D413/12 (EP,US); C07D403/12 (EP,US); A61P9/06 (EP);
C07D235/30 (EP,US); C07D401/12 (EP,US); C07D405/12 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/27]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:BENZIMIDAZOLDERIVATE ALS KALIUMKANALINHIBITOREN[2020/27]
English:BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS[2020/27]
French:DÉRIVÉS DE BENZIMIDAZOLE UTILES COMME INHIBITEURS DE CANAL POTASSIQUE[2020/27]
Entry into regional phase10.03.2020National basic fee paid 
10.03.2020Designation fee(s) paid 
10.03.2020Examination fee paid 
Examination procedure10.03.2020Examination requested  [2020/27]
10.03.2020Date on which the examining division has become responsible
30.09.2020Amendment by applicant (claims and/or description)
26.03.2021Communication of intention to grant the patent
21.06.2021Fee for grant paid
21.06.2021Fee for publishing/printing paid
21.06.2021Receipt of the translation of the claim(s)
Opposition(s)29.04.2022No opposition filed within time limit [2022/27]
Fees paidRenewal fee
27.08.2020Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.08.2018
AL28.07.2021
AT28.07.2021
CY28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
MK28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
LU22.08.2021
BE31.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
[2024/23]
Former [2023/33]HU22.08.2018
AL28.07.2021
AT28.07.2021
CY28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
LU22.08.2021
BE31.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2023/30]AL28.07.2021
AT28.07.2021
CY28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
LU22.08.2021
BE31.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/34]AL28.07.2021
AT28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
LU22.08.2021
BE31.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/29]AL28.07.2021
AT28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SI28.07.2021
SK28.07.2021
SM28.07.2021
LU22.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/25]AT28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SK28.07.2021
SM28.07.2021
LU22.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/24]AT28.07.2021
CZ28.07.2021
DK28.07.2021
EE28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
MC28.07.2021
PL28.07.2021
RO28.07.2021
RS28.07.2021
SE28.07.2021
SK28.07.2021
LU22.08.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/21]AT28.07.2021
DK28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
PL28.07.2021
RS28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/10]AT28.07.2021
FI28.07.2021
HR28.07.2021
LT28.07.2021
LV28.07.2021
PL28.07.2021
RS28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
GR29.10.2021
IS28.11.2021
PT29.11.2021
Former [2022/09]AT28.07.2021
FI28.07.2021
LT28.07.2021
RS28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
PT29.11.2021
Former [2022/08]AT28.07.2021
FI28.07.2021
LT28.07.2021
SE28.07.2021
BG28.10.2021
NO28.10.2021
Former [2022/07]AT28.07.2021
LT28.07.2021
NO28.10.2021
Cited inInternational search[A]WO2006074991  (NEUROSEARCH AS [DK], et al) [A] 1-33* claims 1,10 *;
 [A]WO2013104577  (ACESION PHARMA APS [DK], et al) [A] 1-33 * page 1, line 6 - line 10; claim 1 *;
 [AP]WO2017144183  (ACESION PHARMA APS [DK]) [AP] 1-33 * page 4, line 1 - line 5; claims 1,36 *;
 [A]  - ULRIK S. SOERENSEN ET AL, "Synthesis and Structure-Activity Relationship Studies of 2-(N-Substituted)-aminobenzimidazoles as Potent Negative Gating Modulators of Small Conductance Ca 2+ -Activated K + Channels", JOURNAL OF MEDICINAL CHEMISTRY, (20081211), vol. 51, no. 23, doi:10.1021/jm800809f, ISSN 0022-2623, pages 7625 - 7634, XP055054130 [A] 1-33 * page 7627, paragraph 2 - paragraph 3; table 2 *

DOI:   http://dx.doi.org/10.1021/jm800809f
by applicantWO2006013210
    - WULFF H et al., "Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications", Currrent Medicinal Chemistry, (20070000), vol. 14, doi:doi:10.2174/092986707780831186, pages 1437 - 1457, XP002470707

DOI:   http://dx.doi.org/10.2174/092986707780831186
    - LIEGEOIS J-F et al., "Modulation of small conductance calcium-activated potassium (SK) channels: a new challenge in medicinal chemistry", Current Medicinal Chemistry, (20030000), vol. 10, doi:doi:10.2174/0929867033457908, pages 625 - 647, XP009078299

DOI:   http://dx.doi.org/10.2174/0929867033457908
    - NATTEL S, J. Physiol., (20090000), vol. 587, pages 1385 - 1386
    - DINESS JG; SORENSEN US; NISSEN JD; AL-SHAHIB B; JESPERSEN T; GRUNNET M; HANSEN RS, Circ. Arrhythm. Electrophysiol., (20100000), vol. 3, pages 380 - 90
    - DINESS et al., Hypertension, (20110000), vol. 57, pages 1129 - 1135
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.